Payment overview · 2025
General Payments
$213.26
11 reported records · 6 companies
Healthcare provider profile · identity verified
Thomas Allen Batchelor, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHARLOTTE, NC · NPI 1902839624
Verified facts
What the public records show
CMS Open Payments records show Thomas Allen Batchelor, MD received $213.26 in general payments during 2025 across 11 reported records.
Amgen Inc. accounted for 42.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $89.57 | 42.0% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.82 | 15.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.66 | 11.1% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $22.62 | 10.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.27 | 10.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.32 | 10.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $213.26 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $58.08 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $33.82 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.49 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.66 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 82 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 158 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
153 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
82 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
158 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1132 | 318 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 972 | 306 |
| Levothyroxine Sodium | Levothyroxine Sodium | 780 | 218 |
| Amlodipine Besylate | Amlodipine Besylate | 592 | 172 |
| Omeprazole | Omeprazole | 554 | 165 |
| Losartan Potassium | Losartan Potassium | 542 | 157 |
| Ramipril | Ramipril | 287 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 281 | 79 |
| Gabapentin | Gabapentin | 274 | 91 |
| Trazodone Hcl | Trazodone Hcl | 260 | 89 |
| Lisinopril | Lisinopril | 249 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 224 | 64 |
| Ezetimibe | Ezetimibe | 216 | 73 |
| Metformin Hcl Er | Metformin Hcl | 191 | 62 |
| Zolpidem Tartrate | Zolpidem Tartrate | 190 | 37 |
| Alendronate Sodium | Alendronate Sodium | 183 | 57 |
| Allopurinol | Allopurinol | 177 | 47 |
| Sertraline Hcl | Sertraline Hcl | 177 | 53 |
| Montelukast Sodium | Montelukast Sodium | 174 | 58 |
| Finasteride | Finasteride | 159 | 46 |
| Ozempic | Semaglutide | 158 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 47 |
| Meloxicam | Meloxicam | 157 | 50 |
| Jardiance | Empagliflozin | 153 | 40 |
| Simvastatin | Simvastatin | 153 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 144 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 141 | 59 |
| Fluoxetine Hcl | Fluoxetine Hcl | 140 | 44 |
| Synthroid | Levothyroxine Sodium | 135 | 39 |
| Bupropion Xl | Bupropion Hcl | 130 | 32 |
| Famotidine | Famotidine | 130 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 39 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 125 | 36 |
| Eliquis | Apixaban | 124 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 115 | 32 |
| Metformin Hcl | Metformin Hcl | 115 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 111 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 31 |
| Enalapril Maleate | Enalapril Maleate | 94 | 28 |
| Terazosin Hcl | Terazosin Hcl | 94 | 28 |
| Furosemide | Furosemide | 93 | 30 |
| Potassium Chloride | Potassium Chloride | 90 | 26 |
| Chlorthalidone | Chlorthalidone | 89 | 28 |
| Carvedilol | Carvedilol | 85 | 29 |
| Buspirone Hcl | Buspirone Hcl | 84 | 26 |
| Glimepiride | Glimepiride | 83 | 30 |
| Mounjaro | Tirzepatide | 82 | 16 |
| Celecoxib | Celecoxib | 79 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 21 |
| Ipratropium Bromide | Ipratropium Bromide | 71 | 21 |
| Valacyclovir | Valacyclovir Hcl | 71 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 22 |
| Lovastatin | Lovastatin | 59 | 18 |
| Spironolactone | Spironolactone | 59 | 18 |
| Felodipine Er | Felodipine | 58 | 14 |
| Atenolol | Atenolol | 56 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 17 |
| Valsartan | Valsartan | 51 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 16 |
| Baclofen | Baclofen | 47 | 17 |
| Mirtazapine | Mirtazapine | 47 | 22 |
| Januvia | Sitagliptin Phosphate | 44 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 12 |
| Alprazolam | Alprazolam | 40 | 22 |
| Prednisone | Prednisone | 40 | 32 |
| Clonidine Hcl | Clonidine Hcl | 39 | 14 |
| Pregabalin | Pregabalin | 39 | 14 |
| Sucralfate | Sucralfate | 39 | suppressed |
| Estradiol | Estradiol | 36 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | 11 |
| Ibuprofen | Ibuprofen | 31 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Irbesartan | Irbesartan | 30 | suppressed |
| Klor-Con M20 | Potassium Chloride | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | 12 |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 27 | 25 |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Naproxen | Naproxen | 24 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 19 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Primidone | Primidone | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Prevident | Fluoride (Sodium) | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $213.26 · 11 records | Amgen Inc. | APTIMA, FREESTYLE LIBRE 3, KRYSTEXXA, MOUNJARO, OTEZLA, Ozempic, REPATHA, THINPREP 2000 PROCESSOR, The Cologuard Plus Collection Kit, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error